Gastroenterology vs Immunology — Deal Terms Comparison

Gastroenterology Median Upfront

$529M

Total: $2.7B

Immunology Median Upfront

$480M

Total: $2.5B

Gastroenterology Royalties

7.7%-14.2%

Tiered to 18.2%

Immunology Royalties

13.2%-22.1%

Tiered to 26.1%

Model Your Deal

Market Analysis

Gastroenterology and Immunology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 gastroenterology deals carry a median total deal value of $2.7B with $529M upfront, compared to $2.5B total value and $480M upfront for immunology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

Deal structures differ across therapeutic areas. Gastroenterology deals allocate 20% to upfront and 80% to milestones, while Immunology deals split 19%/81%. Development milestones are $455M for gastroenterology versus $405M for immunology, reflecting the different clinical trial designs and approval standards in each area.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do gastroenterology and immunology deal terms compare?

Gastroenterology Phase 2 deals average $2.7B total value ($529M upfront), while Immunology deals average $2.5B ($480M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.

Which therapeutic area commands higher royalty rates: Gastroenterology or Immunology?

Gastroenterology base royalties range from 7.7% to 14.2%, while Immunology royalties range from 13.2% to 22.1%. Royalty rates reflect pricing power, competitive dynamics, and patent protection characteristics specific to each therapeutic area.

What drives the deal value differences between gastroenterology and immunology?

Key factors include addressable patient population size, clinical trial costs and timelines, regulatory pathway complexity, pricing and reimbursement dynamics, and competitive landscape density. Gastroenterology and Immunology each have unique value drivers that shape deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough